Evidence map›Paper›PMID 40443936›Full record

ArticleFrontiers in public health2025

An exploration of current and future vector-borne disease threats and opportunities for change.

Alexandra Hiscox, Robert T Jones, Jessica Dennehy, Will Dyall, Laura Paris, Freya I Spencer, Fiona Keating, Frederik Seelig, Abhinandan Narendran, Avijit Das and 1 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Zika Virus: A Tale of Two Lineages.Pathogens (Basel, Switzerland) · 2025
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alexandra Hiscox *Arctech Innovation, Dagenham, United Kingdom.
Robert T Jones *Arctech Innovation, Dagenham, United Kingdom.
Jessica DennehyArctech Innovation, Dagenham, United Kingdom.
Will DyallArctech Innovation, Dagenham, United Kingdom.
Laura ParisArctech Innovation, Dagenham, United Kingdom.
Freya I SpencerArctech Innovation, Dagenham, United Kingdom.
Fiona KeatingArctech Innovation, Dagenham, United Kingdom.
Frederik SeeligCenter for Immunology of Viral Infections, Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Abhinandan NarendranReckitt Benckiser (India) Pvt. Ltd., Gurgaon, Haryana, India.
Avijit DasReckitt Benckiser (India) Pvt. Ltd., Gurgaon, Haryana, India.
James G LoganArctech Innovation, Dagenham, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vector-borne diseases, including dengue, threaten the health and livelihoods of over 80% of the world's population, particularly in tropical and subtropical regions. Environmental, ecological, climatic, and socio-economic factors are expected to drive increased transmission, emphasizing the need to identify key threats and prioritize strategies for control. We examined drivers, challenges and potential solutions with global experts, using Brazil and India as case studies. Both countries face rapid population growth, unplanned urbanization and increased exposure to animal reservoirs alongside unique surveillance and control challenges. We advocate for improvements in surveillance systems and capacity, investment in sustainable vector control tools, leveraging of artificial intelligence for outbreak prediction, and fostering public-private partnerships to develop innovative interventions. A multifaceted approach, combining community-led initiatives with advanced technologies, is essential to reducing the burden of vector-borne diseases and preventing future epidemics.

Indexed as

Disease VectorsVector Borne DiseasesAnimalsBrazilDengueDisease OutbreaksHumansIndiaBrazilclimateIndiasurveillancevector-borne disease

Identifiers

PMID40443936
PMCPMC12119574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.